Literature DB >> 12743006

Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation.

Richard C Saumarez1, Lidia Chojnowska, Richard Derksen, Mariusz Pytkowski, Maciej Sterlinski, Christopher L-H Huang, Nicolas Sadoul, Richard N W Hauer, Witold Ruzyłło, Andrew A Grace.   

Abstract

BACKGROUND: Slowed or delayed myocardial activation and dispersed refractoriness predispose to reentrant excitation that may lead to ventricular fibrillation (VF). Increased ventricular electrogram duration (DeltaED) in response to extrastimuli and increased S1S2 coupling intervals at which electrogram duration starts to increase (S1S2delay) are seen both in hypertrophic cardiomyopathy (HCM) in those at risk of VF and in patients with idiopathic VF (IVF). METHODS AND
RESULTS: DeltaED and S1S2delay have been measured using paced electrogram fractionation analysis in 266 patients with noncoronary heart disease. Of these, one group of 61 patients had a history of VF and included 21 HCM, 17 IVF, 13 long-QT syndrome (LQTS), 5 dilated cardiomyopathy (DCM), and 5 others. These were compared with 205 patients with similar diseases with no VF history (non-VF group) and a control group (n=12) without heart disease. Results from HCM VF patients (DeltaED, 19+/-3.3 ms; S1S2delay, 350+/-9.7 ms) differed sharply from observations in HCM non-VF patients (DeltaED, 7.3+/-1.35 ms; S1S2delay, 312+/-6.7 ms; P<0.001). DCM VF patients had longer delays (DeltaED, 14.3+/-5.9; S1S2delay, 344+/-11.2) than DCM non-VF patients (DeltaED, 5.8+/-1.87 ms; S1S2delay, 311+/-5.7 ms; P<0.001), with major differences also seen comparing LQTS VF (DeltaED, 12.4+/-5.3 ms; S1S2delay, 343+/-13.8 ms) and LQTS non-VF patients (DeltaED, 11.0+/-2.7 ms; S1S2delay, 320+/-5.4 ms; P<0.001). IVF patients had both severely abnormal and normal areas of myocardium.
CONCLUSIONS: Slowed or delayed myocardial activation is a common feature in patients with noncoronary heart disease with a history of VF, and its assessment may allow the prospective prediction of VF risk in these patients.

Entities:  

Mesh:

Year:  2003        PMID: 12743006     DOI: 10.1161/01.CIR.0000068342.96569.A1

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

Review 1.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.

Authors:  Michael P Frenneaux
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

2.  Ventricular arrhythmogenesis following slowed conduction in heptanol-treated, Langendorff-perfused mouse hearts.

Authors:  Gary Tse; Sandeep S Hothi; Andrew A Grace; Christopher L-H Huang
Journal:  J Physiol Sci       Date:  2012-01-05       Impact factor: 2.781

Review 3.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

4.  Sudden death is associated with a widened paced QRS complex in noncoronary cardiac disease.

Authors:  Per Otto Schueller; Marcus Guenter Hennersdorf; Bodo Eckehard Strauer
Journal:  J Interv Card Electrophysiol       Date:  2006-03       Impact factor: 1.900

5.  Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1.

Authors:  Richard Balasubramaniam; Andrew A Grace; Richard C Saumarez; Jamie I Vandenberg; Christopher L-H Huang
Journal:  J Physiol       Date:  2003-10-15       Impact factor: 5.182

6.  Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.

Authors:  Ping Liang; Feng Lan; Andrew S Lee; Tingyu Gong; Veronica Sanchez-Freire; Yongming Wang; Sebastian Diecke; Karim Sallam; Joshua W Knowles; Paul J Wang; Patricia K Nguyen; Donald M Bers; Robert C Robbins; Joseph C Wu
Journal:  Circulation       Date:  2013-03-21       Impact factor: 29.690

Review 7.  Murine Electrophysiological Models of Cardiac Arrhythmogenesis.

Authors:  Christopher L-H Huang
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

8.  Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts.

Authors:  Nina S Ghais; Yanmin Zhang; Andrew A Grace; Christopher L-H Huang
Journal:  Exp Physiol       Date:  2008-10-31       Impact factor: 2.969

9.  Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3.

Authors:  Kate S Stokoe; Glyn Thomas; Catharine A Goddard; William H Colledge; Andrew A Grace; Christopher L-H Huang
Journal:  J Physiol       Date:  2006-10-05       Impact factor: 5.182

10.  Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts.

Authors:  Richard Balasubramaniam; Sangeeta Chawla; Lauren Mackenzie; Christof J Schwiening; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2004-07-30       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.